4.8 Article

Optogenetics for in vivo cardiac pacing and resynchronization therapies

Journal

NATURE BIOTECHNOLOGY
Volume 33, Issue 7, Pages 750-754

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.3268

Keywords

-

Funding

  1. NOFAR project from the Office of the Chief Scientist (OCS) in the Israel Ministry of Economy
  2. Israel Science Foundation [1609/14]
  3. Nancy & Stephen Grand Philanthropic Fund

Ask authors/readers for more resources

Abnormalities in the specialized cardiac conduction system may result in slow heart rate or mechanical dyssynchrony. Here we apply optogenetics, widely used to modulate neuronal excitability(1-4), for cardiac pacing and resynchronization. We used adeno-associated virus (AAV) 9 to express the Channelrhodopsin-2 (ChR2) transgene at one or more ventricular sites in rats. This allowed optogenetic pacing of the hearts at different beating frequencies with blue-light illumination both in vivo and in isolated perfused hearts. Optical mapping confirmed that the source of the new pacemaker activity was the site of ChR2 transgene delivery. Notably, diffuse illumination of hearts where the ChR2 transgene was delivered to several ventricular sites resulted in electrical synchronization and significant shortening of ventricular activation times. These findings highlight the unique potential of optogenetics for cardiac pacing and resynchronization therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available